

Sheet 1 of 1

FORM PTO-1449 (REV.7-80)	U. S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 980049.410C1	APPLICATION NO. 10/717,049
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS	
		Richard Martin et al.	
	FILING DATE	GROUP ART UNIT	
	November 18, 2003	1626	

### U. S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
DR	AA	6,541,486	04/01/03	Bitler et al.	514	303	
	AB	6,548,505	04/15/03	Martin et al.	514	252.13	
	AC	6,559,168	05/06/03	Marfat et al.	514	338	
	AD	6,569,874	05/27/03	Pruitt et al.	514	342	
↓	AE	6,586,453	07/01/03	Dhanoa et al.	514	365	
	AF						
	AG						
	AH						
	AI						
	AJ						

### FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AK					
	AL					
	AM					
	AN					
	AO					

### OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AP		Abdel-Megid, M. et al., "A facile synthesis of p-Bis(4-thiazolidinon-3-yl)phenylenes and related systems," <i>Heterocyclic Communications</i> 8(2): 161-168, 2002.
AQ		
AR		

EXAMINER	D. Lambkin	DATE CONSIDERED
----------	------------	-----------------

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

<p style="text-align: center;">O P T E FORM 1449</p> <p style="text-align: center;">JAN 14 2004 LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT</p> <p style="text-align: center;">PATENT &amp; TRADEMARK OFFICE</p>									ATTY. DOCKET NO. 38205-3001B	SERIAL NO. 10/717,049	CONFIRM NO. Unassigned.
									APPLICANT Martin et al.	CUSTOMER NO. 24961	
									FILING DATE November 18, 2003	GROUP Unassigned.	

\* If an asterisk is placed beside the reference number, a copy is provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120, 37 C.F.R. § 1.98(d).

\*\* If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

### U.S. PATENT DOCUMENTS

EXAMINER INITIAL	*Ref. Code	DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
<i>Ole</i>	A	R	E	2	8	8	1	9	05/18/76	Thompson	424	243	12/08/72
	B	0	1	2	0	1	3	7	08/29/02	Houze et al.	540	589	08/31/01
	C	0	1	3	2	2	2	3	09/19/02	Forman et al.	435	4	10/05/01
**	D	0	1	8	1	4	2	0	09/25/03	Bayne et al.	514	63	12/20/02
**	E	0	2	2	8	6	0	7	12/11/03	Wagner et al.	435	6	04/14/03
	F	2	3	8	8	9	6	3	01/21/38	Fre et al.	260	240	01/22/37
	G	2	4	5	4	6	2	9	11/23/48	Brooker	260	240	01/27/40
	H	3	6	2	7	5	3	4	12/14/71	Shiba et al.	96	135	02/21/68
	I	3	6	3	5	9	6	4	01/18/72	Skorcz et al.	260	247.1	02/10/69
	J	3	7	1	0	7	9	5	01/16/73	Higuchi et al.	128	260	09/29/70
	K	4	0	4	4	1	2	6	08/23/77	Cook et al.	424	243	07/09/76
	L	4	0	9	3	7	3	0	06/06/78	Butti et al.	424	270	06/28/76
	M	4	2	3	1	9	3	8	11/04/80	Monaghan et al.	260	343.5	06/15/79
	N	4	2	5	8	1	8	5	03/24/81	Nakao et al.	544	114	04/14/80
	O	4	3	2	8	2	4	5	05/04/82	Yu et al.	424	305	02/13/81
	P	4	3	4	6	2	2	7	08/24/82	Terahara et al.	560	119	06/05/81
	Q	4	3	5	8	6	0	3	11/09/82	Yu	560	2	04/16/81
	R	4	3	6	4	9	2	3	12/21/82	Cook et al.	424	46	04/30/81
	S	4	4	0	9	2	3	9	10/11/83	Yu	424	305	01/21/82

EXAMINER

*D. Lomber*

DATE CONSIDERED

*8/17/05*

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS

<b>U.S. Patent and Trademark Office</b> <b>JAN 16 2004</b> <b>LIST OF PATENTS AND PUBLICATIONS FOR</b> <b>APPLICANT'S INFORMATION DISCLOSURE</b> <b>STATEMENT</b>								ATTY. DOCKET NO. 38205-3001B	SERIAL NO. 10/717,049	CONFIRM NO. Unassigned.
								APPLICANT Martin et al.	CUSTOMER NO. 24961	
								FILING DATE November 18, 2003	GROUP Unassigned.	

\* If an asterisk is placed beside the reference number, a copy is provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120, 37 C.F.R. § 1.98(d).

\*\* If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

### U.S. PATENT DOCUMENTS

EXAMINER INITIAL	*Ref. Code	DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
<i>Dle</i>	T	4	4	1	0	5	4	5	10/18/83	Yu et al.	424	305	05/10/82
	U	4	4	1	4	2	0	9	11/08/83	Cook et al.	424	243	06/13/77
	V	4	4	4	4	7	8	4	04/24/84	Hoffman et al.	424	279	12/18/80
	W	4	5	2	2	8	1	1	06/11/85	Eppstein et al.	514	2	07/08/82
	X	4	9	1	6	1	2	8	04/10/90	Jonas et al.	514	213	06/06/88
	Y	4	9	3	3	3	3	6	06/12/90	Martin et al.	514	222.5	08/09/88
	Z	5	0	3	3	2	5	2	07/23/91	Carter	53	425	07/30/90
	AA	5	0	5	2	5	5	8	10/01/91	Carter	206	439	07/27/90
	AB	5	0	7	0	0	1	2	12/03/91	Nolan et al.	435	6	03/30/88
	AC	5	0	7	1	7	7	3	12/10/91	Evans et al.	436	501	10/20/87
	AD	5	1	7	1	8	5	1	12/15/92	Kim et al.	544	50	03/25/91
	AE	5	1	7	7	0	8	0	01/05/93	Angerbauer et al.	514	277	11/26/91
	AF	5	2	2	1	6	2	3	06/22/93	Legocki et al.	435	252.3	07/19/89
	AG	5	2	7	3	9	9	5	12/28/93	Roth	514	422	02/26/91
	AH	5	2	8	3	1	7	3	02/01/94	Fields et al.	435	6	01/24/90
	AI	5	2	9	8	4	2	9	03/29/94	Evans et al.	436	501	12/10/91
	AJ	5	3	2	3	9	0	7	06/28/94	Kalvelage	206	531	03/15/93
	AK	5	3	5	4	7	7	2	10/11/94	Kathawala	514	414	11/24/93
	AL	5	4	1	4	0	8	8	05/09/95	Von Der Saal et al.	546	158	09/04/90

EXAMINER

*D. Lambkin*

DATE CONSIDERED

*8/17/05*

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS

<p style="margin: 0;">O P E R A T I O N S</p> <p style="margin: 0;">JAN 14 2004</p> <p style="margin: 0;">LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT</p> <p style="margin: 0;">TO ATTENDEE</p>								ATTY. DOCKET NO. 38205-3001B	SERIAL NO. 10/717,049	CONFIRM NO. Unassigned.
								APPLICANT Martin et al.	CUSTOMER NO. 24961	
								FILING DATE November 18, 2003	GROUP Unassigned.	

\* If an asterisk is placed beside the reference number, a copy is provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

\*\* If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

### U.S. PATENT DOCUMENTS

EXAMINER INITIAL	*Ref. Code	DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
DZ	AM	5	4	6	8	6	1	4	11/21/95	Fields et al.	435	6	02/01/94
	AN	5	4	7	6	9	4	5	12/19/95	Ikegawa et al.	548	152	10/19/93
	AO	5	6	1	8	8	3	1	04/08/97	Shishido et al.	514	366	05/16/94
	AP	5	6	5	0	2	8	9	07/22/97	Wood	435	8	01/31/94
	AQ	5	6	6	7	9	7	3	10/07/97	McElroy et al.	514	366	06/07/95
	AR	5	6	7	0	5	3	0	09/23/97	Chen et al.	514	366	06/07/95
	AS	5	6	7	4	7	1	3	10/07/97	McElroy et al.	435	69.7	06/02/95
	AT	5	6	8	3	8	8	8	11/04/97	Campbell	435	8	07/05/94
	AU	5	7	0	7	7	9	4	01/13/98	Fabricius	430	572	11/22/96
	AV	5	7	4	1	6	5	7	04/21/98	Tien et al.	435	18	03/20/95
	AW	5	7	5	7	6	6	1	05/26/98	Surville	364	506	07/01/94
	AX	5	8	4	3	7	4	6	12/01/98	Tatsumi et al.	435	189	01/13/97
	AY	5	9	5	5	6	0	4	09/21/99	Tsien et al.	540	222	10/21/97
	AZ	6	0	7	1	9	5	5	06/06/00	Elias et al.	514	475	02/25/99
	BA	6	1	8	4	2	1	5	02/06/01	Elias et al.	514	182	08/24/99
	BB	6	1	8	7	8	1	4	02/13/01	Elias et al.	514	531	10/29/99
	BC	6	2	9	1	6	7	6	09/18/01	Burke et al.	546	48	03/02/00
	BD	6	3	1	6	5	1	0	11/13/01	Sperber	521	94	04/05/00
✓	BE	6	4	1	6	9	5	7	07/09/02	Evans et al.	435	7.1	10/24/00

EXAMINER

D. Lymburn

DATE CONSIDERED

8/17/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS



FORM PTO-1449.

JAN 14 2004  
PATENT & TRADEMARK OFFICELIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT

ATTY. DOCKET NO. 38205-3001B	SERIAL NO. 10/717,049	CONFIRM NO. Unassigned.
APPLICANT Martin et al.	CUSTOMER NO. 24961	
FILING DATE November 18, 2003	GROUP Unassigned.	

\* If an asterisk is placed beside the reference number, a copy is provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

\*\* If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	*Ref. Code	DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
<i>PL</i>	BF	6	4	5	2	0	3	2	09/17/02	Beard et al.	556.	413	06/09/00
<i>J</i>	BG	6	4	5	8	7	8	9	10/01/02	Forood et al.	514	235.5	09/29/99
<i>J</i>	BH	6	5	2	1	6	6	6	02/18/03	Sircar et al.	514	576	07/19/00

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	*Ref. Code	DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes No
<i>PL</i>	BI	0	0	1	7	3	3	4	03/30/00	PCT			
	BJ	0	0	2	5	1	3	4	05/04/00	PCT			
	BK	0	0	3	7	0	7	7	06/29/00	PCT			
	BL	0	0	4	0	9	6	5	07/13/00	PCT			
	BM	0	0	4	2	0	3	1	07/20/00	PCT			
	BN	0	0	4	9	9	9	2	08/31/00	PCT			
	BO	0	0	5	7	9	1	5	10/05/00	PCT			
	BP	0	0	7	6	5	2	3	12/21/00	PCT			
	BQ	0	0	7	8	9	7	2	12/28/00	PCT			
	BR	0	1	1	7	9	9	4	03/15/01	PCT			
<i>N</i>	BS	0	1	2	0	1	3	7	03/22/01	PCT			
	BT	0	1	2	3	8	8	7	04/05/01	PCT			

EXAMINER


*PL*

DATE CONSIDERED

*PL*

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS



FORM PTO-1449

ATTY. DOCKET NO.  
38205-3001BSERIAL NO.  
10/717,049CONFIRM NO.  
Unassigned.APPLICANT  
Martin et al.CUSTOMER NO.  
24961FILING DATE  
November 18, 2003GROUP  
Unassigned.

\* If an asterisk is placed beside the reference number, a copy is provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120, 37 C.F.R. § 1.98(d).

\*\* If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	*Ref. Code	DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes No
	BU	0	1	6	0	8	1	8	08/23/01	PCT			
	BV	20	01	1	3	6	1	7	01/19/01	JP			+
	BW	0	1	8	2	9	1	7	11/08/01	PCT			
	BX	02	0	6	4	1	2	5	08/22/02	PCT			
	BY	02	0	7	2	5	9	8	09/19/02	PCT			
	BZ	0	2	1	1	7	0	8	02/14/02	PCT			
*	CA	0	3	0	5	9	8	84	07/24/03	PCT			
*	CB	0	3	0	6	0	0	78	07/24/03	PCT			
*	CC	0	3	0	7	6	4	18	09/18/03	PCT			
*	CD	0	3	0	9	9	8	21	12/04/03	PCT			
*	CE	0	3	1	0	6	4	35	12/24/03	PCT			
	CF	0	4	5	4	3	3	0	04/12/91	EP			
	CG	0	5	1	0	2	3	5	04/26/91	EP			
	CH	0	9	8	5	6	8	3	09/09/99	EP			
	CI	1	4	4	9	8	0	0	07/02/64	FR			+
	CJ	1	9	0	8	5	7	0	02/20/69	DE			X
	CK	2	1	1	7	3	3	7	03/12/71	FR			+
	CL	5	2	7	3	5	6		02/05/93	JP			+
	CM	53	1	2	9	6	3	3	11/11/78	JP			+

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MREP-609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS

<p style="text-align: center;"><i>O I P E</i> JAN 16 2004 LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT</p>		ATTY. DOCKET NO. 38205-3001B	SERIAL NO. 10/717,049	CONFIRM NO. Unassigned.
		APPLICANT Martin et al.	CUSTOMER NO. 24961	
		FILING DATE November 18, 2003	GROUP Unassigned.	

\* If an asterisk is placed beside the reference number, a copy is provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

\*\* If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

#### FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	*Ref. Code	DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes      No	
		6	2	2	0	0	5	3						
	CN	6	2	2	0	0	5	3	08/09/94	JP				X
	CO	6	2	3	4	6	3	9	08/23/94	JP				+
	CP	6	2	9	3	6	4	2	10/21/94	JP				X
	CQ	8	4	0	2	1	3	1	06/07/84	PCT				
	CR	8	6	0	3	7	4	9	07/03/86	PCT				
	CS	9	1	0	4	9	7	4	04/18/91	PCT				X
	CT	9	5	1	8	3	8	0	07/06/95	PCT				
	CU	9	7	0	7	1	0	1	02/27/97	PCT				
	CV	9	8	3	2	4	4	4	07/30/98	PCT				
	CW	9	9	2	7	3	6	5	06/03/99	PCT				


+ = An English Derwent Abstract or STN Chem Abstract is provided.

X = An English language equivalent is provided.


#### OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	CX	"Hypolipidemics, HMG-CoA Reductase Inhibitors," <i>Physicians' Desk Reference (PDR)</i> , 50th Ed, (Medical Economics Co), pp. 216 (1996)
	CY	Alberti et al., "Structural characterisation of the mouse nuclear oxysterol receptor genes LXR $\alpha$ and LXR $\beta$ ", <i>Gene</i> , 243:93-103 (2000)
	CZ	Ansel, H.C., (Eds.), in <i>Introduction to Pharmaceutical Dosage Forms Fourth Edition</i> , Philadelphia: Lea & Febiger, pp.125 (1985)

EXAMINER



DATE CONSIDERED



EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS

<p style="text-align: right;">O I P E P FORM PTO-1449 JAN 11 2004 PATENT &amp; TRADEMARK OFFICE</p> <p>LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT</p>	ATTY. DOCKET NO. 38205-3001B	SERIAL NO. 10/717,049	CONFIRM NO. Unassigned.
	APPLICANT Martin et al.	CUSTOMER NO. 24961	
	FILING DATE November 18, 2003	GROUP Unassigned.	

\* If an asterisk is placed beside the reference number, a copy is provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120, 37 C.F.R. § 1.98(d).

\*\* If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

DA	Augustin et al., "Umsetzung des Thiazolo [3,2-a] benzimidazol-3-ons mit Elektrophilen [Reactions of thiazolo [3,2-a]benzimidazol-3-one with electrophiles]", <i>Zeitschrift fur Chemie</i> , <u>29</u> (6):206-207 (1989)
DB	Barrett-Connor, "Epidemiology, Obesity, and Non-Insulin-Dependent Diabetes Mellitus", <i>Epidemiologic Reviews</i> , <u>11</u> :172-181 (1989)
DC	Bellec et al., "Dicationic State of Dithiadiazafulvalene within a TCNQ Charge-Transfer Complex: Generation and Characterization", <i>Chem. Mater.</i> , <u>11</u> :3147-3153 (1999)
DD	Berger et al., "Secreted placental alkaline phosphatase: a powerful new quantitative indicator of gene expression in eukaryotic cells", <i>Gene</i> , <u>66</u> :1-10 (1988)
DE	Bronstein et al., "1,2-Dioxetanes: Novel Chemiluminescent Enzyme Substrates. Applications to Immunoassays", <i>Journal of Bioluminescence and Chemiluminescence</i> , <u>4</u> :99-111 (1989)
DF	Carceller et al., "Design, Synthesis, and Structure-Activity Relationship Studies of Novel 1-[(1-Acy1-4-piperidyl)methyl]-1H-2-methylimidazo[4,5-c] pyridine Derivatives as Potent, Orally Active Platelet-Activating Factor Antagonists", <i>J. Med. Chem.</i> , <u>39</u> :487-493 (1996)
DG	Chiang et al., "Farnesoid X Receptor Responds to Bile Acids and Represses Cholesterol 7 $\alpha$ -Hydroxylase Gene (CYP7A1) Transcription", <i>Journal of Biological Chemistry</i> , <u>275</u> (15):10918-10924 (2000)
DH	Chiasson et al., "The Efficacy of Acarbose in the Treatment of Patients with Non-Insulin-dependent Diabetes Mellitus", <i>Ann. Intern. Med.</i> , <u>121</u> :928-935 (1994)
DI	Chiba et al., "Distinct Retinoid X Receptor-Retinoic Acid Receptor Heterodimers Are Differentially Involved in the Control of Expression of Retinoid Target Genes in F9 Embryonal Carcinoma Cells", <i>Molecular and Cellular Biology</i> , <u>17</u> (6):3013-3020 (1997)
DJ	Coniff, R. and A. Krol, "Acarbose: A Review of US Clinical Experience", <i>Clinical Therapeutics</i> , <u>19</u> (1):16-26 (1997)


EXAMINER

DATE CONSIDERED

8/17/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS



FORM PTO-1449

LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT

ATTY. DOCKET NO. 38205-3001B	SERIAL NO. 10/717,049	CONFIRM NO. Unassigned.
APPLICANT Martin et al.	CUSTOMER NO. 24961	
FILING DATE November 18, 2003	GROUP Unassigned.	

\* If an asterisk is placed beside the reference number, a copy is provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

\*\* If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

DK	Coniff et al., "Multicenter, Placebo-Controlled Trial Comparing Acarbose (BAY g 5421) With Placebo, Tolbutamide, and Tolbutamide-Plus-Acarbose in Non-Insulin-Dependent Diabetes Mellitus", <i>American Journal of Medicine</i> , <u>98</u> :443-451 (1995)
DL	Dains et al., "The Reactions of the Formamidines. VIII. Some Thiazolidone Derivatives", <i>J. Am. Chem. Soc.</i> , <u>43</u> :613-618 (1921)
DM	Davis, J.A. and F.B. Dains, "Some Alkyl Derivatives of Certain Aryl Substituted Thiazolidones", <i>J. Am. Chem. Soc.</i> , <u>57</u> :2627-2630 (1935)
DN	Derwent WPI Acc. No. 13863260 citing Japanese Patent 2001-13617, "Silver halide emulsion, silver halide photosensitive material and thermally developable photosensitive material".
DO	Derwent WPI Acc. No. 9387756 citing Japanese Patent 5-27356, "Silver halide photographic material - contains silver halide particles spectrally sensitised with novel merocyanine dye".
DP	Derwent# 000911469, WPI Acc. No. 1972-71638T/197245 (citing French Patent Number 2117337), "Merocyanine dye sensitizers - contg basic and acidic gps for silver halide emulsions".
DQ	Derwent# 010039860, WPI Acc. No. 1994-307571/199438 (citing Japanese Patent Number 6-234639), "Immunosuppressant contg. Rhodacyanine deriv. - useful in treatment and prevention of e.g. organ, tissue or bone marrow transplant rejection, systemic lupus erythematosus and auto-immune diseases".
DR	Derwent# 002077750, WPI Acc. No. 1978-908270A/197850 (citing Japanese Patent Number 53-129633), "Antistatic silver halide photographic material - contg. oxazolidine deriv. as UV absorber".
DS	Dogan et al., "Synthesis and NMR Studies of Chiral 4-Oxazolidinones and Rhodanines", <i>Tetrahedron</i> , <u>48</u> (35):7157-7164 (1992)
DT	Drobnica et al., "Isothiocyanates. XXXII. Microsynthesis of 3-Substituted Rhodanines", <i>Chem. Zvest</i> , <u>26</u> :538-542 (1972)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS

O I P E  
FORM PTO-1449JAN 14 2004  
PATENT & TRADEMARK OFFICE  
LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT

ATTY. DOCKET NO. 38205-3001B	SERIAL NO. 10/717,049	CONFIRM NO. Unassigned.
APPLICANT Martin et al.	CUSTOMER NO. 24961	
FILING DATE November 18, 2003	GROUP Unassigned.	

\* If an asterisk is placed beside the reference number, a copy is provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120, 37 C.F.R. § 1.98(d).

\*\* If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>M</i>	DU	El-Bahaie et al., "Synthesis of some New Thienopyrimidines containing 4-Thiazolidinone Moiety", <i>J. Indian Chem. Soc.</i> , <u>Vol LXV</u> :695-698 (1988)
	DV	Evans, R.M., "The Steroid and Thyroid Hormone Receptor Superfamily", <i>Science</i> , <u>240</u> :889-895 (1988)
	DW	Fedotov, K.V. and N.N. Romanov "Mesoionic Compounds with a Bridged Nitrogen Atom. 18. Cyclization of (2-Quinazolinylthio) Acetic Acids", <i>Khim Geterotsilcl. Soedin.</i> (6):678-83 (1989) English language edition, [Translated from Russian into English from <i>Khimiya Geterotsiklicheskikh Soedinenii</i> , <u>6</u> :817-822 (1989)]
	DX	Fedotov, K.V., "[Polymethine dyes with 3-oxo-2, 3-dihydrothiazole [3,2-a] pyrimidinium nucleus]", in <i>Ukr. Khim Zh. (Russian Edition)</i> , <u>52</u> (5):514-519 (1986)
	DY	Fedotov et al., "[Mesoionic compounds with a nitrogen bridging atom 12. Study of the cyclization of (2-pyrimidinylthio) acids]", in <i>Khim. Geterotsilcl. Soedin.</i> , <u>7</u> :969-73 (1984)
	DZ	Flier, J.S., "Insulin Receptors and Insulin Resistance", <i>Ann. Rev. Med.</i> , <u>34</u> :145-160 (1983)
	EA	Forman et al., "Identification of a Nuclear Receptor That is Activated by Farnesol Metabolites", <i>Cell</i> , <u>81</u> :687-693 (1995)
	EB	Gangjee et al., "Synthesis and Biological Activities of Tricyclic Conformationally Restricted Tetrahydropyrido Annulated Furo [2,3-d] pyrimidines as Inhibitors of Dihydrofolate Reductases", <i>J. Med. Chem.</i> , <u>41</u> :1409-1416 (1998)
	EC	Garcia et al., "Morbidity and Mortality in Diabetics in the Framingham Population", <i>Diabetes</i> , <u>23</u> :105-111 (1974)
	ED	Glass, C.K., "Differential Recognition of Target Genes by Nuclear Receptor Monomers, Dimers, and Heterodimers", <i>Endocrine Reviews</i> , <u>15</u> (3):391-407 (1994)
<i>✓</i>	EE	Glickman et al., "A Comparison of ALPHAScreen, TR-FRET, and TRF as Assay Methods for FXR Nuclear Receptors", <i>Journal of Biomolecular Screening</i> , <u>7</u> (1):3-10 (2002)

EXAMINER

DATE CONSIDERED

*8/7/03*

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS

O P E FORM PTO-1449 JAN 16 2004 LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT PATENT & TRADEMARK OFFICE		ATTY. DOCKET NO. 38205-3001B	SERIAL NO. 10/717,049	CONFIRM NO. Unassigned.
		APPLICANT Martin et al.	CUSTOMER NO. 24961	
		FILING DATE November 18, 2003	GROUP Unassigned.	

\* If an asterisk is placed beside the reference number, a copy is provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

\*\* If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

#### OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)


EF	Gorman et al., "Recombinant Genomes Which Express Chloramphenicol Acetyltransferase in Mammalian Cells", <i>Molecular and Cellular Biology</i> , <u>2</u> (9):1044-1051 (1982)
EG	Greenberg, M.M. and J.D. Kahl, "Template-Free Segmental synthesis of Oligonucleotides Containing Nonnative Linkages", <i>J. Org. Chem.</i> , <u>66</u> :7151-7154 (2001)
EH	Haffner, S.M., "Management of Dyslipidemia in Adults with Diabetes", <i>Diabetes Care</i> , <u>21</u> (1):160-178 (1998)
EI	Heyman et al., "9-Cis Retinoic Acid is a High Affinity Ligand for the Retinoid X Receptor", <i>Cell</i> , <u>68</u> :397-406 (1992)
EJ	Howard et al., "Lipoprotein Composition in Diabetes Mellitus", <i>Atherosclerosis</i> , <u>30</u> :153-162 (1978)
EK	Humphlett, W.J., and R.W. Lamon, "4-Thiazoline-2-thiones. I. The Structure of Intermediate 4-Hydroxythiazolidine-2-thiones", <i>J. Org. Chem.</i> , <u>29</u> :2146-2148 (1964)
EL	IUPAC-IUB Commission on Biochemical Nomenclature Abbreviated Nomenclature of Synthetic Polypeptides (Polymerized Amino Acids) Revised Recommendations (1971)", <i>Biochemistry</i> , <u>11</u> (5):942-944 (1972)
EM	Iwamoto et al., "Effect of Combination Therapy of Troglitazone and Sulphonylureas in Patients with Type 2 Diabetes Who Were Poorly controlled by Sulphonylurea Therapy Alone", <i>Diabetic Medicine</i> , <u>13</u> :365-370 (1996)
EN	Janowski et al., "An oxysterol signalling pathway mediated by the nuclear receptor LXRa", <i>Nature</i> , <u>383</u> :728-731 (1996)
EO	Joslin, E.P., "Arteriosclerosis and Diabetes", <i>Annals of Clinical Medicine</i> , Vol V. No. 12: 1061-1080 (1927)
EP	Kain, S.R., "Use fo Secreted Alkaline Phosphatase as a Reporter of Gene Expression in Mammalian Cells", <i>Methods in Molecular Biology</i> , <u>63</u> :49-60 (1997)
EQ	Kaplan, et al. (Eds.), "Cardiovascular Diseases", in <i>Health and Human Behavior</i> , New York: McGraw-Hill, Inc. pp. 206-242 (1993)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS



FORM PTO-1449

LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT

ATTY. DOCKET NO. 38205-3001B	SERIAL NO. 10/717,049	CONFIRM NO. Unassigned.
APPLICANT Martin et al.	CUSTOMER NO. 24961	
FILING DATE November 18, 2003	GROUP Unassigned.	

\* If an asterisk is placed beside the reference number, a copy is provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

\*\* If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>BB</i>	ER	Kassab, R.R. "Some Reactions with 2-Imino 4-Thiazolidone", <i>Al-Azhar Bull. Sci.</i> , <u>8</u> (1): 1-6 (1997)
	ES	Katritzky et al., "Syntheses of 2-Alkylamino- and 2-Dialkylamino-4, 6-diarylpyridines and 2, 4, 6-Trisubstituted Pyrimidines Using solid-Phase-Bound Chalcones", <i>J. Comb. Chem.</i> , <u>2</u> :182-185 (2000)
	ET	Katritzky et al. (Eds.), "Thiazoles and their Benzo Derivatives," <i>Comprehensive Heterocyclic Chemistry II: a review of the literature 1982-1985: the structure, reactions, synthesis, and uses of heterocyclic compounds</i> Netherlands: Elsevier Science, Ltd. pp.316-321 (1996) [CD-ROM Supplement]
	EU	Knowler et al., "Obesity in the Pima Indians: its magnitude and relationship with diabetes", <i>Am. J. Clin. Nutr.</i> , <u>53</u> :1543S-1551S (1991)
	EV	Kwiterovich, Jr., P.O. "State-of-the-art Update and Review: Clinical Trials of Lipid-Lowering Agents", <i>Am. J. Cardiol.</i> , <u>82</u> (12A):3U-17U (1998)
	EW	Laakso, M. and S. Lehto, "Epidemiology of macrovascular disease in diabetes," <i>Diabetes Reviews</i> , <u>5</u> (4):294-315 (1997)
	EX	Lehmann et al., "Activation of the Nuclear Receptor LXR by Oxysterols Defines a New Hormone Response Pathway", <i>Journal of Biological Chemistry</i> , <u>272</u> (6):3137-3140 (1997)
	EY	Levin et al., "9-Cis retinoic acid stereoisomer binds and activates the nuclear receptor RXR $\alpha$ ", <i>Nature</i> , <u>355</u> :359-361 (1992)
	EZ	Mahler, R.J. and M.L. Adler, "Type 2 Diabetes Mellitus: Update on Diagnosis, Pathophysiology, and Treatment", <i>Journal of Clinical Endocrinology and Metabolism</i> , <u>84</u> (4):1165-1171 (1999)
<i>BB</i>	FA	Makishima et al., "Identification of a Nuclear Receptor for Bile Acids", <i>Science</i> , <u>284</u> :1362-1365 (1999)
<i>BB</i>	FB	Mangelsdorf et al., "The RXR Heterodimers and Orphan Receptors", <i>Cell</i> , <u>83</u> :841-850 (1995)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS

<p style="text-align: center;">O I P E USPTO-1449 <i>JAN 14 2004</i> LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT <i>PATENT &amp; TRADEMARK OFFICE</i></p>	ATTY. DOCKET NO. 38205-3001B	SERIAL NO. 10/717,049	CONFIRM NO. Unassigned.
	APPLICANT Martin et al.	CUSTOMER NO. 24961	
	FILING DATE November 18, 2003	GROUP Unassigned.	

\* If an asterisk is placed beside the reference number, a copy is provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

\*\* If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

#### OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

M	FC	Mangelsdorf et al., "Characterization of three RXR genes that mediate the action of 9-cis retinoic acid", <i>Genes and Development</i> , <u>6</u> :329-344 (1992)
	FD	Mehta, M. R. and J.P. Trivedi, "Synthesis of 2,3-disubstituted-4-thiazolidinones and 3,5-diaminothiophene-2-carbo-xylic acid derivatives", <i>Indian Journal of Chemistry</i> , <u>29B</u> :1146-1153 (1990)
	FE	Mukherjee et al., "Ligand and coactivator recruitment preferences of peroxisome proliferator activated receptor $\alpha$ ", <i>Journal of Steroid Biochemistry and Molecular Biology</i> , <u>81</u> :217-225 (2002)
	FF	Nogradi, <i>Medicinal Chemistry A Biochemical Approach</i> , Oxofrd University Press, New York, pp. 388-392 (1985).
	FG	O'Malley, B.W. "Editorial: Did Eucaryotic Steroid Receptors Evolve from Intracrine Gene Regulators?", <i>Endocrinology</i> , <u>125</u> :1119-1120 (1989)
	FH	Owicki, "Fluorescence and Anisotropy in High Throughput Screening: Perspectives and Primer," <i>Journal of Biomolecular Screening</i> , <u>5</u> (5):297-306 (2000)
	FI	Parks et al., "Bile Acids: Natural Ligands for an Orphan Nuclear Receptor", <i>Science</i> , <u>284</u> :1365-1368 (1999)
	FJ	Peet et al., "The LXR $\alpha$ s: a new class of oxysterol receptors", <i>Curr. Opin. Genet. Dev.</i> , <u>8</u> (5):571-575 (1998)
	FK	Peet et al., "Cholesterol and Bile Acid Metabolism Are Impaired in Mice Lacking the Nuclear Oxysterol Receptor LXR $\alpha$ ", <i>Cell</i> , <u>93</u> :693-704 (1998)
	FL	Reaven, G.M., "Pathophysiology of Insulin Resistance in Human Disease", <i>Physiological Reviews</i> , <u>75</u> :473-486 (1995)
	FM	Reaven, G.M., "Insulin Resistance and Human Disease: A Short History", <i>J. Basic and Clin. Phys. and Pharm.</i> , <u>9</u> :387-406 (1998)
	FN	Seada et al., "Synthesis and Biological Activity of Some New Thiazolidinones," <i>Indian J. Heterocycl. Chem.</i> , <u>3</u> :81-86 (1993)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS

<p style="text-align: right;">O I P F O R M P T O - 1 4 4 9</p> <p style="text-align: center;">JAN 16 2004 LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT</p> <p style="text-align: center;">PATENT &amp; TRADEMARK OFFICE</p>		ATTY. DOCKET NO. 38205-3001B	SERIAL NO. 10/717,049	CONFIRM NO. Unassigned.
		APPLICANT Martin et al.	CUSTOMER NO. 24961.	
		FILING DATE November 18, 2003	GROUP Unassigned.	

\* If an asterisk is placed beside the reference number, a copy is provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

\*\* If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

**OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)**

FO	Seol et al., "Isolation of Proteins That Interact Specifically with the Retinoid X Receptor: Two Novel Orphan Receptors", <i>Molecular Endocrinology</i> , <u>9</u> :72-85 (1995)
FP	Sinal et al., "Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis"; <i>Cell</i> , <u>102</u> :731-744 (2000)
FQ	Song et al., "Ubiquitous Receptor: Structures, Immunocytochemical Localization, and Modulation of Gene Activation by Receptors for Retinoic Acids and Thyroid Hormones", <i>Ann. N.Y. Acad. Sci.</i> , <u>761</u> :38-49 (1995)
FR	Still et al., "Rapid Chromatographic Technique for Preparative Separations with Moderate Resolution", <i>J. Org. Chem.</i> , <u>43</u> (14):2923-2925 (1978)
FS	STN (Chem. Abstracts) Document No. 105:154660, Chem. Abstract of Russian language article by Fedotov et al., "Polymethine dyes with 3-oxo-2, 3-dihydrothiazole [3,2-a] pyrimidinium nucleus", <i>Ukrainskii Khimicheskii Zhurnal (Russian edition)</i> , <u>52</u> (5):514-19 (1986)
FT	STN (Chem. Abstracts) Document No. 66:105907, Chem. Abstract of French patent application FR1449800, "Sensitizing dyes", published 07/02/64.
FU	STN (Chem. Abstracts) Document No. 101:191838, Chem. Abstract of Russian language article by Fedotov et al., "Mesoionic compounds with a nitrogen bridging atom. 12. Study of the cyclization of (2-pyrimidinylthio) acetic acids", <i>Khimiya Geterotsiklichesikh Soedinenii</i> , <u>7</u> :969-73 (1984)
FV	STN (Chem. Abstracts) Document No. 112:20939, Chem. Abstract of German language article by Augustin et al., "Reactions of thiazolo [3,2-a] benzimidazol-3-one with electrophiles", <i>Zeitschrift fuer Chemie</i> , <u>29</u> (6):206-7 (1989)
FW	Tomkins, G.M., "The Metabolic Code", <i>Science</i> , <u>189</u> :760-763 (1975)
FX	Tsien, R.Y., "The Green Fluorescent Protein", <i>Annu. Rev. Biochem.</i> , <u>67</u> :509-544 (1998)
FY	Turner et al., "Insulin resistance, impaired glucose tolerance and non-insulin-dependent diabetes, pathologic mechanisms and treatment: Current status and therapeutic possibilites", <i>Progress in Drug Research</i> , <u>51</u> :33-94 (1998)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS

O I P E O R D PTO-1449

JAN 14 2004  
LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT

ATTY. DOCKET NO. 38205-3001B	SERIAL NO. 10/717,049	CONFIRM NO. Unassigned.
APPLICANT Martin et al.	CUSTOMER NO. 24961	
FILING DATE November 18, 2003	GROUP Unassigned.	

\* If an asterisk is placed beside the reference number, a copy is provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

\*\* If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

FZ	UKPDS 28: A Randomized Trial of Efficacy of Early Addition of Metformin in Sulfonylurea-Treated Type 2 Diabetes", <i>Diabetes Care</i> , <u>21</u> (1):87-92 (1998)
GA	Urizar et al., "The Farnesoid X-activated Receptor Mediates Bile Acid Activation of Phospholipid Transfer Protein Gene Expression", <i>Journal of Biological Chemistry</i> , <u>275</u> (50):39313-39317 (2000)
GB	Van Allan, J.A., "2-Carboxymethylmercaptobenzimidazole and Related Compounds", <i>J. Org. Chem.</i> , <u>21</u> :24-27 (1956)
GC	Wan et al., "Hepatocyte-Specific Mutation Establishes Retinoid X Receptor $\alpha$ as a Heterodimeric Integrator of Multiple Physiological Processes in the Liver", <i>Molecular and Cellular Biology</i> , <u>20</u> (12):4436-4444 (2000)
GD	Wang et al., "Endogenous Bile Acids Are Ligands for the Nuclear Receptor FXR/BAR", <i>Molecular Cell</i> , <u>3</u> :543-553 (1999)
GE	Willy et al., "LXR, a nuclear receptor that defines a distinct retinoid response pathway", <i>Genes and Development</i> , <u>9</u> :1033-1045 (1995)
GF	Wilson et al., "Disorders of Lipid Metabolism", Chapter 23, <i>Textbook of Endocrinology</i> , 9th Edition, (W.B. Sanders Company, Philadelphia, Pa., U.S.A.), 1998
GG	Yalpani et al., "Cholesterol-Lowering Drugs", <i>Chemistry and Industry</i> , pp.85-89 (5 February 1996)
GH	Zhou et al., "Nuclear Receptors Have Distinct Affinities for Coactivators: Characterization by Fluorescence Resonance Energy Transfer", <i>Molecular Endocrinology</i> , <u>12</u> (10):1594-1604 (1998)

EXAMINER

DATE CONSIDERED

8/17/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS